Introduction
Thorotrast (thorium dioxide) was introduced in 1930 as a diagnostic test for visualization of the liver and spleen, renal pelvis, body cavities and for angiography. Following widespread usage it began to be discontinued in 1947 as complications arising from its use developed. A case is now reported of myelofibrosis in a patient who had received thorotrast 29 years previously.
Cas history
A 73-year-old lady presented in December of 1975 with a 6-week history of malaise and dyspnoea on exertion. In 1947 she had undergone an operation to remove cervical sympathetic ganglia because of Raynaud's phenomenon. There was no other past medical history of significance.
On examination she appeared anaemic, with signs of mild congestive cardiac failure. There was no lymphadenopathy or hepatosplenomegaly.
A blood count showed a pancytopenia: red cell count 1 22 x 1012/1, Hb 4 g/dl, WCC 2-4 x 109/1 (20% neutrophils, 79 % lymphocytes, 1 % myelocytes), platelets 55 x 109/1. The peripheral blood film showed anisocytosis and occasional target cells. Careful scrutiny revealed a few tear-shaped poikilocytes, nucleated red blood cells, myelocytes and HowellJolly bodies. A few blast cells were also seen. Routine biochemistry was normal, as were vitamin B12, folate and serum iron levels. Plasma urate and leucocyte alkaline phosphatase score were also normal. Sternal marrow punctures twice resulted in a dry tap. An iliac crest trephine biopsy was performed and showed decreased fat spaces and fibrosis. Silver stains showed abundant reticulin fibres, the picture was that of myelofibrosis ( Fig. 1.) . A plain Correspondence: Dr A. G. Arnold, The Chest Clinic, Churchill Hospital, Headington, Oxford.
X-ray of the abdomen suggested previous thorotrast administration, with a characteristically shrunken spleen and abdominal lymph nodes which appeared to be calcified (Fig. 2) . Using a gamma scintillation counter, radioactive emission was recorded over the surface of the spleen, liver and thigh. The results were 1777, 3512 and 3622 counts/100 s respectively, compared with a background count of 20/100 s.
Retrospective analysis of old case notes revealed that the patient had received an injection of thorotrast into her brachial artery immediately before her operation in 1947. This had been given to demonstrate the arterial circulation.
Despite normal folate levels, and the absence of megaloblasts, prophylactic folate was prescribed. The patient survived for 8 months after the initial presentation, although she required increasingly frequent blood transfusions and developed several minor infections. She was then admitted in a collapsed state, with Gram-negative septicaemia, and died. A peripheral blood film during her final illness showed 26% blast cells but was otherwise similar to previous films.
Gross post-mortem examination, 19 hr after death, revealed a heart of normal size, with a vegetation on the posterior cusp of the mitral valve. The liver was enlarged and contained scattered abscesses, whilst the spleen was small and firm. Red marrow extended to the centres of the long bones.
On microscopic examination the mitral valve showed non-bacterial thrombotic endocarditis. Thorotrast was found lying free within the connective tissue stroma of the liver (Fig. 3) . The iron stores were increased and there was evidence of extra-medullary haemopoiesis, with numerous megakaryocytes. The spleen showed loss of the normal follicular architecture, with deposits of thorotrast in the stroma, and haemosiderin pigment in the histiocytes.
Sections of bone marrow from the sternum, iliac crest and vertebrae showed a hyperplastic marrow. The cells had a uniform, immature appearance, and normal fat spaces were not seen. Numerous haemosiderin-laden phagocytes were present, and iron stores were increased. 
Discussion
Thorium is a radioactive substance with a halflife of 1P4 x 1010 years. It emits predominantly a radiation, which is of short penetration, and small amounts of 3 and y radiation. The peak emission of ax radiation can occur up to 25 years after administration because the thorium decays to form other radioactive substances which are themselves strong a emitters (Prezyna, Ayres and Mulry, 1953) .
Following administration, thorotrast is rapidly concentrated in the liver, spleen and bone marrow, where it remains.
A survey of 1100 patients who had received thorotrast showed a high incidence of complications which included granulomata and malignancies at the site of thorotrast administration, hepatic fibrosis, hepatic neoplasms and blood dyscrasias (Horta et al., 1965) . The haematological complications can occur after a long latent period, and range from abnormal red blood cell morphology (Langlands and Williamson, 1967) , to acute leukaemia and aplastic anaemia (Johnson et al., 1977) . Myelofibrosis has been documented following nuclear explosions (Anderson, Hoshino and Yamamoto, 1964) , and 7 cases have been described following thorotrast administration (Johnson et al., 1977) .
Acute or malignant myelofibrosis was first described in 1963 (Lewis and Szur, 1963) and is basically an accelerated version of the classical variety. Particular features emphasized are the absence of splenomegaly, pancytopenia and a rapidly downhill course. The condition is thought to differ from acute leukaemia because of the reticulin proliferation in the marrow and relative absence of blast cells, although small numbers are seen in the peripheral blood film. There is debate as to whether acute myelofibrosis is a separate entity since a certain amount of marrow fibrosis can be seen in acute leukaemia (Sanerkin, 1964) . The fibroblastic response in acute myelofibrosis appears to be a secondary reactive phenomenon, rather than part of a neoplastic process (Van Slyck, Weiss and Dully, 1970) . However, an increase in marrow reticulin remains an important index of myelofibrosis, whilst a large proportion of marrow blast cells is necessary for the definite diagnosis of acute leukaemia (Beard and Hamilton Fairley, 1974) . Since cases of advanced chronic myelofibrosis often have a considerable number of blasts in the peripheral blood, and since the exact significance of histological evidence of extra-medullary haemopoiesis is uncertain (Modan, 1975) , it is difficult to judge whether these cases of acute myelofibrosis are really acute leukaemias. Despite this difficulty in nomenclature such acute cases undoubtedly occur, with several recent case reports in the literature (Lubin, Rozen and Rywlin, 1976; Libnoch et al., 1977) . There has been one case report of the apparent co-existence of acute myelofibrosis and acute myeloid leukaemia (Patel, Shah and Rhee, 1976) .
The case which has now been described resembles the picture of acute myelofibrosis, with a rapidly downhill course over a period of only 8 months. Since thorotrast was isolated from the bone marrow at post-mortem it was undoubtedly of aetiological significance. The absence of splenomegaly in this patient was due to splenic atrophy following thorotrast administration. Diminished haematopoietic reserve might have been responsible for the rapid course of this patient's illness, since damage to her reticuloendothelial system might have limited extramedullary haemopoiesis (Johnson et al. 1977) . The findings suggest a terminal blastic phase to the patient's illness, and the probable transition to an acute leukaemia. Similar marrow changes at postmortem have been seen in recent cases of acute myelofibrosis, with hypercellularity and infiltration with blast cells (Lubin et al., 1976; Libnoch et al., 1977 
